Related Experiment Videos
Treating mood disorders during pregnancy: safety considerations.
Malin Eberhard-Gran1, Anne Eskild, Stein Opjordsmoen
1Division of Epidemiology, Norwegian Institute of Public Health, Postbox 4404 Nydalen, N-0403 Oslo, Norway. malin.eberhard-gran@fhi.no
Drug Safety
|July 29, 2005
Summary
Treating maternal mood disorders during pregnancy requires careful drug selection. While some antidepressants show no major malformation risk, others like lithium and valproic acid increase fetal risks, necessitating risk-benefit assessment.
Area of Science:
- Obstetrics and Gynecology
- Perinatology
- Psychiatry
Background:
- Mood disorders during pregnancy can negatively impact maternal self-care and fetal outcomes.
- Pharmacological treatment is sometimes necessary, requiring careful consideration of risks and benefits.
Purpose of the Study:
- To review current knowledge on the safety of psychotropic medications used during pregnancy.
- To assess teratogenicity, neonatal, and long-term neurobehavioral effects of various mood disorder treatments.
Main Methods:
- Systematic review of existing studies on psychotropic drug use in pregnancy.
- Analysis of data on major malformations, neonatal adaptation, and neurobehavioral outcomes.
Main Results:
- Selective serotonin reuptuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are not linked to major malformations but may cause neonatal adaptation issues.
- Mood stabilizers like lithium, carbamazepine, and valproic acid are associated with increased fetal malformation risks.
- Benzodiazepines in the first trimester may increase orofacial cleft risk; novel antipsychotics have limited data but no observed malformations.
Conclusions:
- Balancing the risks of fetal exposure to psychotropic medications against the risks of untreated maternal mood disorders is crucial.
- Further research, particularly randomized controlled trials, is needed to fully understand the long-term neurobehavioral effects of these medications on offspring.